Renal Transplant Clinical Trial
Official title:
Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study
BACKGROUND: Antibody-mediated humoral rejection is currently a critical question in renal
transplant recipient with immunological risk factors such as pre transplant donor-specific
anti HLA antibodies (DSA). The immunosuppressive management of the patients is still not well
defined and improving both short and long-term graft outcome remains a challenging question.
Recent experimental data suggest that Belatacept could induce B cell anergy , induce
regulatory B cell and decrease Ig production. These findings are strengthened by the results
of both phase II and III clinical studies, showing a significant lower incidence of DSA in
patients treated with Belatacept compared to recipients receiving a conventional
immunosuppressive regimen with calcineurin inhibitors (CNI).
Primary objective will be the incidence of clinical and subclinical humoral rejection
(According to BANFF 2011 Criteria). Secondary objectives will include one-year graft and
patient survival, renal function at M12 (MDRD), incidence of cellular rejection (M 12), level
of proteinuria (M3 and M12) and DSA outcome (outcome of DSA MFI at JO, M3 and M12). Inclusion
period will be of two years. DSA identification and quantitative analysis before and after
transplantation will be centralized in only one HLA laboratory Unit (Hospital Saint Louis)
for providing results homogeneity.
According to previous clinical studies, the incidence of Acute Antibody Mediated Humoral
Rejection is close to 20% in patients with mild immunological risk defined by the presence of
DSA at the time of transplant with mean fluorescence intensity (MFI) between 1000 and 3000
(Luminex). In order to demonstrate a significant reduction (40%) of AAMR and sAAMR incidence,
91 patients will be included in this study. Results will be compared to a cohort matched for
age, sex, immunological risk factor (DSA), time of transplant, transplant center and grafted
with a similar immunosuppressive regimen including CNI instead of Belatacept
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01220050 -
Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism
|
Phase 2 | |
| Completed |
NCT00820469 -
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
|
Phase 4 | |
| Completed |
NCT00239005 -
Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation
|
Phase 4 | |
| Completed |
NCT00270153 -
The Use of ACE Inhibitors in the Early Renal Post-transplant Period
|
Phase 1 | |
| Completed |
NCT02711826 -
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT03837522 -
Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies
|
N/A | |
| Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
| Completed |
NCT01256294 -
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
|
Phase 4 | |
| Suspended |
NCT01059292 -
TIPE2 Associated With Kidney Transplant
|
N/A | |
| Completed |
NCT00547040 -
Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
|
||
| Suspended |
NCT03043339 -
Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt
|
||
| Completed |
NCT02581644 -
Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries
|
N/A | |
| Completed |
NCT01728012 -
Long-term Cardiovascular Risk Following Successful Renal Transplantation
|
N/A | |
| Terminated |
NCT01011114 -
Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
|
N/A | |
| Completed |
NCT02117596 -
Calcineurin Inhibitor Based Immunosuppression Withdrawal
|
N/A | |
| Completed |
NCT00555373 -
Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression
|
N/A | |
| Recruiting |
NCT05156086 -
Safety and Effectiveness of COVID-19 Vaccine in Kidney Transplant Recipients
|
||
| Completed |
NCT01334333 -
Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
|
Phase 4 | |
| Recruiting |
NCT03107858 -
The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function
|
Phase 2/Phase 3 | |
| Completed |
NCT00352547 -
Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation
|
N/A |